Drugs / DSP-1083
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06753331 | Dec 2024 → Dec 2030 expected | Parkinson disease | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-28 | Sumitomo Pharma America, Inc. | Regulatory Initiation of Company-sponsored Clinical Study on iPS Cell-derived Dopaminergic Progenitor Cells for Parkinson’s Disease in the United States sumitomo-pharma.com ↗
The IND application, submitted in February 2024, received FDA approval after a 30-day review, and preparations for the clinical study are being finalized. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-28 | Sumitomo Pharma America, Inc. | Initiation of Company-sponsored Clinical Study on iPS Cell-derived Dopaminergic Progenitor Cells for Parkinson’s Disease in the United States sumitomo-pharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSP-1083 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06753331 ↗ |
| Modality | Cell therapy | “implantation of dopaminergic progenitor cells derived from induced pluripotent stem cells (DSP-1083)” NCT06753331 ↗ |
| Route | Other | “Stereotactic Intracranial Implantation of DSP-1083” NCT06753331 ↗ |